官方服务：
资源简介：
# QS-21 & 3D-MPL in o/w emulsion.*A: 92UG037 B: 92US715 Bal: Ba-L C:96ZM651 E: 93TH976.
应用场景：
创建时间：
2015-12-02
相关数据集
The founder virus HIV envelope was developed based on the consensus sequence of 1894 subtype C founder virus sequences. The protein has been used as an immunogen has as a SOSIP.664 trimer shows antigenically relevant epitopes and improved immunogenicity.. The subtype C Founder Virus HIV Envelope
This study includes the development and characterization of a putative immunogen that resembles the HIV-1 native spike, is antigenically relevant and is able to produce broadly neutralizing antibodies
NIAID Data Ecosystem70
Comparative Immunogenicity of HIV-1 Clade C Envelope Proteins for Prime/Boost Studies
BackgroundPrevious clinical efficacy trials failed to support the continued development of recombinant gp120 (rgp120) as a candidate HIV vaccine. However, the recent RV144 HIV vaccine trial in Thailan
NIAID Data Ecosystem20
Enhancement of Antibodies to the Human Immunodeficiency Virus Type 1 Envelope by Using the Molecular Adjuvant C3d
DNA vaccines expressing the envelope (Env) protein of the human immunodeficiency virus have been relatively ineffective at generating high-titer, long-lasting, neutralizing antibodies in a variety of
PubMed Central10
Fold differences in mean chemokine levels from mice immunized with co-administration of Ov-103 and Ov-RAL-2 with adjuvant.
Fold differences in mean chemokine levels from mice immunized with co-administration of Ov-103 and Ov-RAL-2 with adjuvant.
Figshare2016-09-28 更新20
Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial
Trial Design HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor immunogenicity and recently, safety concerns associated with human adenovirus serotype-5 vectors. To t
NIAID Data Ecosystem20
